Why is Parmax Pharma falling/rising?

As of 07-Nov, Parmax Pharma Ltd is experiencing a decline in its stock price, currently at 32.60, which reflects a decrease of 0.4 or 1.21%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 6.19% during this period. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. The delivery volume has also seen a significant drop, with a reported volume of 192 on 06 Nov, which is down by 88.57% compared to the 5-day average. The stock's performance over the past week shows a decline of 5.15%, while it has decreased by 26.33% year-to-date, indicating a persistent downward trend.
In the broader market context, the Sensex has shown a slight decline of 0.86% over the past week, which is less severe than Parmax Pharma's performance. While the benchmark has gained 1.57% over the last month and 6.50% year-to-date, Parmax Pharma's significant underperformance highlights its struggles relative to the overall market. The lack of available positive or negative factors further complicates the outlook, as there are no specific catalysts identified that could potentially reverse the current trend.